All Stories

  1. Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2019, Dove Medical Press

    Eeva Piitulainen, Dr Hanan A Tanash, Adriana-Maria Hiller

  2. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2019, Dove Medical Press

    Dr Hanan A Tanash, Eeva Piitulainen

  3. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2018, Dove Medical Press

    Eeva Piitulainen, Sandra Diaz Ruiz, Dr Hanan A Tanash

  4. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2017, Dove Medical Press

    Dr Hanan A Tanash, Eeva Piitulainen

  5. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2016, Dove Medical Press

    Dr Hanan A Tanash, Eeva Piitulainen

  6. Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS)

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2016, Dove Medical Press

    Eeva Piitulainen, Annika Rosengren, Christer Janson, Anna-Carin Olin